| 115 | 10 | 9 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 探究贝伐珠单抗联合卡铂紫杉醇化疗对Ⅲ B～Ⅳ期卵巢癌患者免疫功能及无进展生存期(PFS)的影响。方法 本研究为一项回顾性研究，以2020年1月至2022年10月于上海交通大学医学院附属瑞金医院确诊为ⅢB～Ⅳ期的卵巢癌65例患者作为研究对象，根据治疗方法不同分为研究组(n=33)和对照组(n=32)。两组患者均行手术治疗，对照组术后采用“卡铂+紫杉醇”化疗，研究组在对照组治疗方法的基础上加用贝伐珠单抗，比较两组治疗效果。结果 两组总有效率、6个月生存率、12个月生存率和不良反应发生率差异均无统计学意义(均P>0.05)。与治疗前相比，两组患者经过治疗后，其血清糖类抗原125(CA125)、血清癌胚抗原(CEA)、CD4+和CD4+/CD8+水平均下降(均P<0.05)，且研究组CA125、CEA、CD4+和CD4+/CD8+水平均低于对照组[(56.44±6.94) U·L-1 vs (87.19±7.36) U·L-1,(6.94±1.36) ng·m L-1 vs (10.91±1.84) ng·m L-1,(30.13±3.57)%vs (32.26±4.71)%,(0.85±0.19) vs (0.96±0.17)](t=17.335,9.914,2.059,2.457，均P<0.05)；研究组CD8+高于对照组[(35.45±3.39)%vs (33.60±3.51)%,t=16.832,P<0.05]。研究组PFS明显长于对照组[(5.41±1.63)个月vs (3.86±1.39)个月，t=4.119,P<0.05]。结论 贝伐珠单抗联合一线化疗能提高ⅢB～Ⅳ期卵巢癌患者疗效，改善免疫功能，延长PFS。
Abstract：Objective To investigate the effect of bevacizumab combined with"carboplatin+paclitaxel"chemotherapy on immune function and progression free survival (PFS) in patients with stageⅢB-Ⅳovarian cancer.Methods The clinical data of65 patients who were diagnosed as suffering from stageⅢ B-Ⅳovarian cancer in Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from January 2020 to October 2022 were retrospectively analyzed.They were divided into the study group (n=33) and control group (n=32) according to different treatment methods.All the 65 patients received surgical treatment.After surgery,the patients in the control group underwent"carboplatin+paclitaxel"chemotherapy after surgery while those in the study group received bevacizumab based on the treatment regimen of the control group.The clinical efficacy was compared between the two groups.Results The differences of the total effective rate,6-month survival rate,12-month survival rate and incidence of adverse reactions were not statistically significant between the two groups (all P>0.05).Compared with those before treatment,the levels of serum carbohydrate antigen 125 (CA125),carcinoembryonic antigen (CEA),CD4~+and CD4+/CD8~+in both groups were decreased after treatment (all P<0.05).The levels of CA125,CEA,CD4+,and CD4+/CD8~+in the study group were lower than those in the control ((56.44±6.94) U·L-1 vs (87.19±7.36) U·L-1,(6.94±1.36) ng·m L-1 vs (10.91±1.84) ng·m L-1,(30.13±3.57)%vs (32.26±4.71)%,(0.85±0.19) vs (0.96±0.17))(t=17.335,9.914,2.059,2.457,all P<0.05),while the CD8~+levels in the study group was higher than that in the control ((35.45±3.39)%vs (33.60±3.51)%,t=16.832,P<0.05).The PFS of the study group was significantly longer than that of the control ((5.41±1.63) months vs (3.86±1.39) months,t=4.119,P<0.05).Conclusion The application of bevacizumab combined with"carboplatin+paclitaxel"chemotherapy in patients with stageⅢ B-Ⅳovarian cancer can effectively improve immune function,promote the efficacy and prolong PFS.
[1] Armstrong DK, Alvarez RD, Backes FJ, et al. NCCN Guidelines?Insights:Ovarian Cancer, Version 3.2022[J].J Natl Compr Canc Netw, 2022, 20(9):972-980.
[2]杨晓雨，陈东宇，王红心，等.中国女性卵巢癌流行现状和趋势及预测分析[J].重庆医科大学学报，2022,47(9):1030-1035.
[3] Samuel D, Diaz-Barbe A, Pinto A, et al. Hereditary ovarian carcinoma:cancer pathogenesis looking beyond BRCA1 and BRCA2[J].Cells, 2022, 11(3):539.
[4]刘宗超，李哲轩，张阳，等.2020全球癌症统计报告解读[J].肿瘤综合治疗电子杂志，2021,7(2):1-13.
[5]张国楠，石宇，王登凤.助力实现RO，减少铂耐药的发生——晚期卵巢癌广泛性壁层腹膜切除术的临床意义[J].中国实用妇科与产科杂志，2022,38(1):9-12.
[6]宓淑芳，张立梅，李沫，等.贝伐珠单抗治疗铂耐药卵巢癌、输卵管癌、腹膜癌患者的临床研究[J].中国临床药理学杂志，2023,39(23):3379-3383.
[7] Ray-Coquard I, Leary A, Pignata S, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer:final overall survival results from the PAOLA-1/ENGOT-ov25 trial[J].Ann Oncol, 2023, 34(8):681-692.
[8]卢淮武，林荣春，林仲秋. 2 0 1 7 N C C N《卵巢癌临床实践指南(第一版)》解读[J].中国实用妇科与产科杂志，2017,33(5):485-493.
[9]朱熠，张国楠.卵巢癌、输卵管癌和腹膜癌FIGO2013分期和临床意义的解读[J].肿瘤预防与治疗，2015(5):291-294.
[10] Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST:evolving considerations for PET response criteria in solid tumors[J].J Nucl Med, 2009, 50(Suppl 1):122S-150S.
[11] Miller KD, Fidler-Benaoudia M, Keegan TH, et al. Cancer statistics for adolescents and young adults, 2020[J].CA Cancer J Clin,2020, 70(6):443-459.
[12] Frenel JS, Kim JW, Aryal N, et al. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance:post-hoc analyses of the SOLO2/ENGOT Ov-21 trial[J].Ann Oncol, 2022, 33(10):1021-1028.
[13] DiSilvestro P, Banerjee S, Colombo N, et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation:the SOLO1/GOG 3004 trial[J].J Clin Oncol, 2023, 41(3):609-617.
[14] Harter P, Mouret-Reynier MA, Pignata S, et al. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phaseⅢPAOLA-1/ENGOT-ov25 trial[J].Gynecol Oncol, 2022,164(2):254-264.
[15] Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer(NRG Oncology/Gynecologic Oncology Group study GOG-0213):a multicentre,open-label, randomised, phase 3 trial[J].Lancet Oncol, 2017,18(6):779-791.
[16]邱刚，苏颖杰，王萌萌，等.紫杉醇联合顺铂化疗致胆汁淤积性药物性肝损伤1例[J].中国药物应用与监测，2019,16(2):124-126.
[17] Li WZ, Lv X, Hu D, et al. Effect of induction chemotherapy with paclitaxel, cisplatin, and capecitabine vs cisplatin and fluorouracil on failure-free survival for patients with stageⅣA toⅣB nasopharyngeal carcinoma:a multicenter phase 3 randomized clinical trial[J].JAMA Oncol, 2022, 8(5):706-714.
[18] Prager GW, Taieb J, Fakih M, et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer[J].N Engl J Med, 2023, 388(18):1657-1667.
[19]中国抗癌协会宫颈癌专业委员会.妇科肿瘤腹腔热灌注治疗临床应用指南(2023年版)[J].中国实用妇科与产科杂志，2023,39(9):926-934.
[20] Raj MS, Pittala K, Wallace SJ, et al. Abdominal wall reconstruction after extirpation of a 140-pound primary ovarian mucinous adenocarcinoma[J].Cureus, 2023, 15(2):e35542.
[21] Nakai H, Matsumura N. The roles and limitations of bevacizumab in the treatment of ovarian cancer[J].Int J Clin Oncol, 2022,27(7):1120-1126.
[22] Aigner KR, Gailhofer S, Aigner K. Hypoxic isolated abdominal perfusion breaks through chemoresistance in recurrent FIGO stageⅢC andⅣovarian cancer[J].Mol Clin Oncol, 2021, 14(6):129.
[23]尹智坚，李才锐，赵薇，等.贝伐单抗不同途径给药对角膜移植术后兔角膜血管内皮生长因子表达的影响[J].中国老年学杂志，2022,42(23):5793-5796.
[24]张佳慧，郭其森，张初峰，等.EGFR 20外显子插入突变晚期NSCLC化疗联合免疫治疗对比联合贝伐珠单抗临床分析[J].中华肿瘤防治杂志，2022,29(11):828-833.
[25]曾艳斌，张海霞，周海辉，等.临床药师参与下的贝伐珠单抗不良反应主动监测与分析[J].中国医院药学杂志，2023,43(16):1840-1845.
基本信息:
中图分类号:R737.31
引用信息:
[1]邱玲琳,冯炜炜,陆晓兰,等.贝伐珠单抗联合卡铂紫杉醇化疗对Ⅲ B～Ⅳ期卵巢癌患者免疫功能及无进展生存期的影响[J].中国药物应用与监测,2024,21(04):394-398.
2024-08-25
2024-08-25